Immuno-checkpoint inhibitors (ICI) are becoming an integral part of advanced cancer treatment. ICI-induced colitis (ICI-C) is one of the most common adverse events that is usually treated with steroids, infliximab or vedolizumab. All these agents are immune-suppressants that are associated with certain risks. We describe here an alternative treatment for ICI-C without diminishing ICI effect or causing toxicity.